Clinical features | MOG-IgG-positive n = 35 | MOG-IgG-negative n = 50 | Univariate analyses p value |
Basic Information | |||
Gender, male, n (%) | 21 (60) | 28 (56) | 0.713 |
Onset age, months, median (range) | 69 (20–138) | 76 (13–178) | 0.317 |
Disease duration, days, median (range) | 10 (1–30)* | 6 (0.5–30) | 0.048 |
Hospital stay, days, median (range) | 17 (6–35) | 16 (7–40) | 0.567 |
With respiratory symptoms, n (%) | 10 (28.6) | 17 (34) | 0.771 |
Onset at winter or spring, n (%) | 23 (65.7) | 24 (48) | 0.358 |
Clinical characteristics | |||
Encephalopathy, n (%) | |||
Altered consciousness, n (%) | 21 (60) | 38 (76) | 0.152 |
Behavioral changes, n (%) | 14 (40) | 12 (24) | 0.152 |
Fever, n (%) | 23 (65.7) | 37 (74) | 0.472 |
Headache, n (%) | 15 (42.9) | 26 (52) | 0.509 |
Vomiting, n (%) | 13 (37.1) | 22 (44) | 0.655 |
Seizures, n (%) | 8 (22.3) | 13 (26) | 0.801 |
Optic neuritis, n (%) | 6 (17.1) | 4 (8) | 0.305 |
Meningeal involvement, n (%) | 11 (31.4)* | 4 (8) | 0.008 |
Ataxia, n (%) | 3 (8.6) | 6 (12) | 0.731 |
Limb weakness, n (%) | 13 (37.1) | 17 (34) | 0.820 |
CSF analysis | |||
Pleocytosis, n (%) | 29 (82.9) | 32 (64) | 0.858 |
Protein elevation, n (%) | 13 (37.1) | 15 (30) | 0.550 |
Positive OB, n (%) | 5 (14.3) | 3 (6) | 0.265 |
Therapeutic characteristics | |||
Neurological sequel, n(%) | 5 (14.3) | 11 (22) | 0.413 |
Relapse, n (%) | 5 (14.3)* | 1 (2) | 0.030 |
IVIG therapy, n (%) | 21 (60) | 35 (70) | 0.339 |
Methylprednisolone therapy | 35 (100) | 50 (100) | 1.000 |